Edesa Biotech prices $25.0M public offering of shares and warrants

Edesa Biotech, Inc.

Offering: 3,870,500 common shares plus warrants and 675,000 pre-funded warrants; combined price $5.50 per share/warrant unit.
Gross proceeds ~$25.0M, net ~$23.1M after fees; expected close Aug 21, 2026.
Common share warrants exercisable at $7.50, expire 18 months or 30 days after Phase 2 vitiligo topline data for EB06.
Underwriters granted 30-day option for 681,825 additional shares and warrants.
Proceeds for general corporate purposes incl. working capital, R&D and manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.